NCYT:LON
Novacyt SA
39,50 GBX
arrow_downward
-0,25%(-0,100) 1K
16-okt, 16:35:25 (GMT+1) · GBX
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoNCYT tikeri uchun statistika yaratilmoqda...
Ochish
39,60 GBX
Yuqori
39,68 GBX
Past
39,20 GBX
Bozor kapitali
32,41 mln
Oʻrtacha hajm
102,63 ming
Hajmi
12,22 ming
52 haftalik eng yuqori
86,00 GBX
52 haftalik eng past
26,60 GBX
Muomaladagi aksiyalar
37,66 mln
Xodimlar soni
228
Ochish
39,60 GBX
Yuqori
39,68 GBX
Past
39,20 GBX
Bozor kapitali
32,41 mln
Oʻrtacha hajm
102,63 ming
Hajmi
12,22 ming
52 haftalik eng yuqori
86,00 GBX
52 haftalik eng past
26,60 GBX
Muomaladagi aksiyalar
37,66 mln
Xodimlar soni
228
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Yahoo Finance
·
22 daqiqa oldin
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
Simply Wall Street
·
33 daqiqa oldin
Did Genetic Response Data Just Shift Madrigal Pharmaceuticals (MDGL) Investment Narrative?
MarketWatch
·
45 daqiqa oldin
It was another great week for the average stock as market leadership shifts away from tech
CNN
·
17 soat oldin
Nasdaq sinks more than 2% as investors raise questions about AI debt
Profil
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Novacyt SA haqida